NCT02734771 (BV mini CHP) is a Phase 2 clinical trial of Brentuximab vedotin in Diffuse Large B-Cell Lymphoma, sponsored by Patrick Reagan.

Who is sponsoring NCT02734771?

NCT02734771 is sponsored by Patrick Reagan.

What drugs are being tested in NCT02734771?

Interventions in NCT02734771: Brentuximab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone.

What condition does NCT02734771 study?

NCT02734771 studies Diffuse Large B-Cell Lymphoma.

Is NCT02734771 still recruiting?

NCT02734771 is currently active, enrolled. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT02734771: BV mini CHP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL

Active, enrolled Phase 2 Last updated 6 August 2025

What this trial tests

Phase 2 trial testing Brentuximab vedotin in Diffuse Large B-Cell Lymphoma in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 June 2016

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Patrick Reagan
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 June 2016
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	2 locations across United States

Drugs / interventions tested

Brentuximab vedotin — full drug profile →
Rituximab — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Doxorubicin
Prednisone (prednisone) — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →

Sponsor

Patrick Reagan

Who can join

75 and older, any sex, with Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent of Subjects Completing Regimen
Time frame: 20 weeks
Number of subjects who complete all 6 cycles of the therapy divided by the total number of subjects.

Sponsor's own description

This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab vedotin.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.
Škubník J, Pavlíčková VS, Ruml T, Rimpelová S. · · 2021 · cited 86× · PMID 34571726 · DOI 10.3390/biology10090849
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Muñoz-Calleja C. · · 2017 · cited 39× · PMID 29387053 · DOI 10.3389/fimmu.2017.01936
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.
Papageorgiou SG, Thomopoulos TP, Liaskas A, Vassilakopoulos TP. · · 2022 · cited 19× · PMID 35454825 · DOI 10.3390/cancers14081917
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.
Chaudhari J, Shah NN. · · 2025 · PMID 40805213 · DOI 10.3390/cancers17152517

Verify or expand the search:

Other trials of Brentuximab vedotin

Trials testing the same drug.

NCT05149768 — Open Label Extension Study of Brentuximab Vedotin in Early dcSSc · Phase 2 · recruiting
NCT05922904 — PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lym · Phase 2 · active not recruiting
NCT05313243 — Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma · Phase 2 · recruiting
NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · Phase 1 · recruiting
NCT05442554 — A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma · Phase 4 · completed

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02734771 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Patrick Reagan
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02734771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing